Lácha J, Jirka J, Nouza M, Chadimová M, Rossmann P
Klinika nefrologie a Patologicko-anatomické pracovistĕ Institutu klinické a experimentální medicíny, Praha.
Cas Lek Cesk. 1994 Sep 26;133(18):562-5.
In conjunction with organ transplantation and subsequent treatment there is a number of influences which potentiate the development and possibly the growth of tumours. This applies naturally also to transplantations of the kidneys. The objective of the present study was to assess the frequency and type of tumours in patients after renal transplantation and compare these results with data of the at present most extensive worldwide register in Cincinnati (CTTR).
The authors analyzed a group of 879 patients where within the period between March 21, 1966 and Sept. 29, 1992 a total of 989 renal transplantations were performed from dead relations-934 or from living relations (55); in 38 patients combined transplantations of kidney and pancreas were performed. The group comprised 59% men and 41% women. In the course of years the pattern of prophylactic immunosuppression changed: up to 1984 the basic drug was azathioprin combined with prednisone, during the same year cyclosporin A was introduced as a rule in a triple combination with azathioprin and prednisone; less frequent was the combination of cyclosporin A and prednisone. For antirejection treatment corticoids were used, later supplemented with polyclonal or monoclonal antibodies. During the period 1966-1992 tumourous diseases were diagnosed in 32 patients (3.64%); in two of these patients; combined transplantation of the kidney and pancreas was performed (5.3%). There was no difference in the frequency of tumours in patients with immunosuppressive medication (azathioprin with prednisone-3.80%) and cyclosporin A (3.51%). The mean age of the patients at the time of diagnosis of the tumour was 50.2 years, the interval after transplantation was 42.2 months (in patients treated with azathioprin 57 months, in the group treated with cyclosporin A 29.2 months). As far as the location of tumours is concerned, tumours of the skin predominated 25% (as compared with CTTR where it was 30%), tumours of the patient's own kidneys 21.9% and of the urinary pathways 15.6%, tumours of the gastrointestinal tract 12.5%, lymphomas in 9% (as compared with 15-20% in CTTR), tumours of the lungs 6.25% and other localizations also 6.25%. Some tumours frequently encountered in the population (lung cancer, cancer of the prostate, breast, colorectal carcinoma) are less frequent in patients after transplantation (CTTR); however, this fact was not confirmed by the authors. In renal tumours and tumours of the efferent urinary pathways data on analgetic nephropathy were encountered very frequently.
The prevalence of tumours of various organs in patients after transplantations of the kidneys are not a frequent but a very serious complication. Its causes are multifactorial. The group after renal transplantations in the Czech Repubic has some deviations as compared with CTTR as regards affection of organs.
器官移植及后续治疗伴随着多种影响因素,这些因素会促进肿瘤的发生甚至生长。这自然也适用于肾脏移植。本研究的目的是评估肾移植患者中肿瘤的发生率和类型,并将这些结果与辛辛那提目前全球最广泛的登记处(CTTR)的数据进行比较。
作者分析了一组879例患者,在1966年3月21日至1992年9月29日期间,共进行了989例肾移植,其中934例来自已故亲属,55例来自在世亲属;38例患者进行了肾胰联合移植。该组男性占59%,女性占41%。多年来,预防性免疫抑制模式发生了变化:1984年以前,基本药物是硫唑嘌呤联合泼尼松,同年环孢素A通常与硫唑嘌呤和泼尼松三联使用;环孢素A与泼尼松联合使用的情况较少。抗排斥治疗使用皮质类固醇,后来补充了多克隆或单克隆抗体。在1966 - 1992年期间,32例患者(3.64%)被诊断患有肿瘤性疾病;其中2例患者进行了肾胰联合移植(5.3%)。使用免疫抑制药物(硫唑嘌呤与泼尼松 - 3.80%)和环孢素A(3.51%)的患者中肿瘤发生率没有差异。肿瘤诊断时患者的平均年龄为50.2岁,移植后的间隔时间为42.2个月(使用硫唑嘌呤治疗的患者为57个月,使用环孢素A治疗的组为29.2个月)。就肿瘤的发生部位而言,皮肤肿瘤占主导,为25%(与CTTR的30%相比),患者自身肾脏的肿瘤占21.9%,尿路肿瘤占15.6%,胃肠道肿瘤占12.5%,淋巴瘤占9%(与CTTR的15 - 20%相比),肺部肿瘤占6.25%,其他部位也占6.25%。人群中常见的一些肿瘤(肺癌、前列腺癌、乳腺癌、结直肠癌)在移植后患者中较少见(CTTR);然而,作者并未证实这一事实。在肾肿瘤和传出尿路肿瘤中,经常遇到镇痛性肾病的数据。
肾移植患者中各种器官肿瘤的发生率虽不高,但却是一种非常严重的并发症。其病因是多方面的。与CTTR相比,捷克共和国肾移植后的患者组在器官受累方面存在一些偏差。